Amicus Therapeutics Stock Target Price and Analyst Consensus
| FOLD Stock | USD 5.96 0.33 5.25% |
The current analyst and expert consensus on Amicus Therapeutics is Strong Buy, with 8 strong buy opinions. The current projected Amicus Therapeutics target price consensus is 15.82 with 12 analyst opinions. Check out Macroaxis Advice on Amicus Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.The most common way Amicus Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Amicus Therapeutics executives and customers to further validate their buy or sell advice. Amicus Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Amicus Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 3.0853.
Lowest Forecast 14.39 | Highest Forecast 17.56 | Target Price 15.82 |
It's important to approach Amicus Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Amicus Therapeutics Target Price Consensus
Amicus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Amicus Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Amicus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Amicus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Amicus Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAmicus Therapeutics Target Price Projection
Amicus Therapeutics' current and average target prices are 5.96 and 15.82, respectively. The current price of Amicus Therapeutics is the price at which Amicus Therapeutics is currently trading. On the other hand, Amicus Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Amicus Therapeutics Market Quote on 21st of July 2025
Target Price
Analyst Consensus On Amicus Therapeutics Target Price
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Amicus Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Amicus Therapeutics' financials, market performance, and future outlook by experienced professionals. Amicus Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Amicus Therapeutics price targets
Amicus Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Amicus Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Amicus Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Amicus Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Amicus Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Amicus Therapeutics is a key component of Amicus Therapeutics valuation and have some predictive power on the future returns of a Amicus Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested over 30 shares | |
 | Driverless Cars Invested few shares | |
 | Business Services Invested few shares | |
 | Chemicals Invested over 40 shares | |
 | Dividend Beast Invested over 50 shares | |
 | Hedge Favorites Invested over 100 shares | |
 | Cash Cows Invested few shares | |
 | Macroaxis Index Invested few shares | |
 | Social Domain Invested few shares | |
 | Disruptive Technologies Invested few shares | |
 | Banking Invested over 40 shares | |
 | Automobiles and Trucks Invested over 50 shares |
Check out Macroaxis Advice on Amicus Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Please note, the presentation of Amicus Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amicus Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Amicus Therapeutics' management manipulating its earnings.